Neuromyelitis Optica Spectrum Disorder Market

1
(No Transcript)
2
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis optica (NMO) and NMO Spectrum
Disorder (NMOSD), also known as Devic's disease,
is an autoimmune disorder in which immune system
cells and antibodies primarily attack the optic
nerves and the spinal cord.
01
The damage to optic nerves produces swelling and
inflammation that cause pain and loss of vision
the damage to the spinal cord causes paralysis in
the legs or arms, and problems with bladder and
bowel function.
02
NMOSD symptoms can be optic neuritis or myelitis.
Optic neuritis is inflammation of the optic nerve
leading to pain inside the eye, which rapidly is
followed by loss of clear vision.
03
04
There is a strong association with a personal or
family history of autoimmunity. It is more common
in female as compared to male.

• DelveInsight 2019 All rights reserved

3
NMOSD Epidemiology
NMO/NMOSD affects 0.4 per 10,000 population in
the EU that is approximately 2,564 people in the
UK.
Prevalences of definite NMO and NMOSD were higher
in Southern Japan than in Northern Japan.
The prevalence of Neuromyelitis Optica Spectrum
Disorder was 3.42 in 100,000.
The positivity for anti-aquaporin - 4 antibody
was 78.6 percent, and the mean age at onset was
45.2 years.
NMOSD crude prevalence was 4.1/100,000 in
northern Japan with a higher number of female
than male patients.

• DelveInsight 2019 All rights reserved

4
NMOSD Market Outlook
There is no approved therapy for NMOSD treatment
in market, but several off-label therapies are
used. NMOSD Treatment is divided into two groups
suppression of acute inflammatory relapse and
prevention of future relapses.
The therapies under development are focused on
novel approaches for NMOSD treatment.
Since, there is no approved therapy for the
NMOSD, there is a need for several effective
therapies to treat the patients and to enhance
NMOSD market. The clinical trials are being
conducted for launch of various therapies that
could target NMOSD patients and would be
beneficial for the increment of NMOSD market
during the forecast period.
Owing to the rise in awareness and NMOSD
prevalence, NMOSD market size shall increase
during forecast period (2019- 2028).

• DelveInsight 2019 All rights reserved

5
NMOSD Emerging Drugs and Companies
Drug Satralizumab (SA237) by Chugai
Pharmaceutical/ Roche
NMOSD market dynamics is expected to change in
coming years due to diagnosis methodologies,
improvement, raising awareness of the disease,
incremental healthcare spending across the world
and expected launch of NMOSD emerging therapies
during the forecast period of 2019-2028.
Drug Soliris By Alexion Pharma
Drug MEDI-551 by Viela Bio

• DelveInsight 2019 All rights reserved

6
Complete Information
For complete information on
Neuromyelitis Optica Spectrum Disorder Market
Insights, Epidemiology Market Forecast-2028
please click the link below
CLICK HERE
OR
Write Us At 
info_at_delveinsight.com

• DelveInsight 2019 All rights reserved

• DelveInsight 2019 All rights reserved

7
About DelveInsight
1
2
3

• DelveInsight 2019 All rights reserved

8
Services by DelveInsight
PharmDelve
Forecasting
Opportunity Assessment
Consulting
Report Store
Market Intelligence
Competitive Analysis
Pipeline

• DelveInsight 2019 All rights reserved

9
Contact Us
info_at_delveinsight.com
91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight

• DelveInsight 2019 All rights reserved

10
Contact Us
info_at_delveinsight.com
91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight

• DelveInsight 2019 All rights reserved